Skip to content
AwardedSpainGoods

Suministro del principio activo denominado "BLINATUMOMAB 38,5 MCG VIAL POLVO INTRAVENOSA "para el Hospital Universitario de Gran Canaria Dr. Negrín.

Published
Published 26 June 2026

Overview

The Hospital Universitario de Gran Canaria Dr. Negrín procured the active pharmaceutical ingredient blinatumomab 38.5 mcg intravenous powder vial. The contract, valued at €115,385, was awarded to AMGEN, S.A. on 6 May 2026 and is now complete.

Key details

Country
Spain
Status
Awarded
Category
Goods
Procedure
Direct
Published
26 June 2026
Classification (CPV)
Various medicinal products

Award outcome

Awarded value
€115,385
Award date
6 May 2026
Winner
  • AMGEN, S.A

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    26 June 2026

Contracting authority

  • Dirección Gerencia Hospital Universitario de Gran Canaria Doctor Negrín

    Procuring entity

    Las Palmas de Gran Canaria, Spain

    ID_PLATAFORMA: 21050930148853

    Authority website ↗

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Suministro del principio activo denominado "BLINATUMOMAB 38,5 MCG VIAL POLVO INTRAVENOSA "para el Hospital Universitario de Gran Canaria Dr. Negrín. — won by AMGEN, S.A — Skim